Alzheimer’s Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What’s Next?
For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
Beam Therapeutics Inc (NASDAQ:BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ:APLS) to create new gene-editing treatments for complement-driven diseases. The partnership will…
72 Biggest Movers From Yesterday
Gainers
Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share.
‘Halftime Report’ Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond
Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP).
In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body.
Why Gene Editing Stocks Are Trading Higher Again Today
Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its investigational CRISPR therapy.
Unusual Options Activity Insight: Intellia Therapeutics
Shares of Intellia Therapeutics (NASDAQ:NTLA) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $183.36.
Stocks That Hit 52-Week Highs On Wednesday
This morning 132 companies reached new 52-week highs.